AI-assisted, human-published
07/17/2026 /Funding Events
Trellis Bioscience Raises $9 Million for Phase 2 Trial of Antibody Treatment
Trellis Bioscience secures $9 million in Series C financing to support the completion of its Phase 2 trial of calpurbatug (TRL1068), an investigational monoclonal antibody treatment for chronic prosthetic joint infections.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com